Comparative Pharmacology
Head-to-head clinical analysis: STRONTIUM CHLORIDE SR 89 versus XENOVIEW.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STRONTIUM CHLORIDE SR 89 versus XENOVIEW.
STRONTIUM CHLORIDE SR-89 vs XENOVIEW
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Strontium-89 is a calcium mimetic that localizes to bone, particularly areas of increased osteoblastic activity, emitting beta radiation that causes DNA damage and cell death in metastatic tumor cells.
Xenoview is a paramagnetic contrast agent for MRI that enhances T1 relaxation by shortening the longitudinal relaxation time of water protons in tissues where it accumulates, thereby increasing signal intensity on T1-weighted images.
148 MBq (4 mCi) intravenously over 1-2 minutes, single dose. Repeat after 3-6 months if needed.
Not applicable (diagnostic agent, not therapeutic); refer to imaging protocol.
None Documented
None Documented
Terminal elimination half-life: 50.5 days (range 33–65 days). Reflects slow clearance from bone; clinical effect persists due to long skeletal retention.
Terminal elimination half-life is 3-5 hours in patients with normal renal function; may be prolonged in renal impairment.
Primarily renal (urinary) excretion; approximately 50-80% of absorbed dose eliminated via urine over 7 days. Fecal elimination is negligible (<5%).
Primarily renal excretion (60-70% unchanged drug), with 20-25% biliary/fecal elimination.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical